Search results
Showing 1891 to 1905 of 2042 results for guidelines
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
HealthVCF for detecting vertebral compression fractures on CT scans (MIB267)
NICE has developed a medtech innovation briefing (MIB) on HealthVCF for detecting vertebral compression fractures on CT scans .
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
populations. This research could have a significant impact upon updates of this guideline.Important outcomes could include:- offending...
The section of the NICE impact lung cancer report looking at the diagnosis and staging process of lung cancer care.
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
Guide to the methods of technology appraisal 2013
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued [GID-TA10334]
Discontinued [GID-TA10072]
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices
Costs: charging for technology appraisals and highly specialised technologies
Information about charging for our technology appraisal (TA) and highly specialised technologies (HST) assessments.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Discontinued [GID-TA10310]